GSK ViiV Healthcare's Apretude authorised for HIV prevention in EU
GSK ViiV Healthcare's Apretude authorised for HIV prevention in EU
Source: directorstalkinterviews.com
Page 2 - Efficacy Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Efficacy Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Efficacy Study Today - Breaking & Trending Today
Lindamood-Bell Receives Funding for a Collaborative Research Grant to Accelerate Growth in Reading for Elementary Students
/PRNewswire/ -- Lindamood-Bell, in collaboration with the American Institutes for Research® (AIR®), has been awarded funding for "An Efficacy Study of the...
Source: prnewswire.com
New and emerging treatments for myasthenia gravis
### Key messages > New immunomodulatory therapeutics hold promise for the future treatment of myasthenia gravis, say DeHart-McCoyle and colleagues Myasthenia gravis is an antibody mediated autoimmune disorder affecting the function of the neuromuscular junction, leading to fluctuating weakness of
Source: bmj.com
Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor Is Safe, Clinically Effective in MS
Tolebrutinib is an Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.
Source: ajmc.com
Tolebrutinib 96-Week MRI Results Promising for the Investigational BTK Inhibitor
Two-year data on magnetic resonance imaging (MRI), efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.
Source: ajmc.com